129 related articles for article (PubMed ID: 32946682)
1. Temperature does matter-an additional dimension in kinase inhibitor development.
Strauch M; Heyd F
FEBS J; 2021 May; 288(10):3148-3153. PubMed ID: 32946682
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the SR protein-phosphorylating CLK kinases of Plasmodium falciparum impairs blood stage replication and malaria transmission.
Kern S; Agarwal S; Huber K; Gehring AP; Strödke B; Wirth CC; Brügl T; Abodo LO; Dandekar T; Doerig C; Fischer R; Tobin AB; Alam MM; Bracher F; Pradel G
PLoS One; 2014; 9(9):e105732. PubMed ID: 25188378
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of desaza analogues of annomontine and canthin-4-one alkaloids.
Strödke B; Gehring AP; Bracher F
Arch Pharm (Weinheim); 2015 Feb; 348(2):125-31. PubMed ID: 25664630
[TBL] [Abstract][Full Text] [Related]
4. Validation of the protein kinase
Alam MM; Sanchez-Azqueta A; Janha O; Flannery EL; Mahindra A; Mapesa K; Char AB; Sriranganadane D; Brancucci NMB; Antonova-Koch Y; Crouch K; Simwela NV; Millar SB; Akinwale J; Mitcheson D; Solyakov L; Dudek K; Jones C; Zapatero C; Doerig C; Nwakanma DC; Vázquez MJ; Colmenarejo G; Lafuente-Monasterio MJ; Leon ML; Godoi PHC; Elkins JM; Waters AP; Jamieson AG; Álvaro EF; Ranford-Cartwright LC; Marti M; Winzeler EA; Gamo FJ; Tobin AB
Science; 2019 Aug; 365(6456):. PubMed ID: 31467193
[TBL] [Abstract][Full Text] [Related]
5. Development of Potent
Mahindra A; Janha O; Mapesa K; Sanchez-Azqueta A; Alam MM; Amambua-Ngwa A; Nwakanma DC; Tobin AB; Jamieson AG
J Med Chem; 2020 Sep; 63(17):9300-9315. PubMed ID: 32787140
[TBL] [Abstract][Full Text] [Related]
6. In silico Screening and Evaluation of Plasmodium falciparum Protein Kinase 5 (PK5) Inhibitors.
Eubanks AL; Perkins MM; Sylvester K; Ganley JG; Posfai D; Sanschargrin PC; Hong J; Sliz P; Derbyshire ER
ChemMedChem; 2018 Dec; 13(23):2479-2483. PubMed ID: 30328274
[TBL] [Abstract][Full Text] [Related]
7. Screening and In Vitro Evaluation of Potential Plasmodium falciparum Leucyl Aminopeptidase Inhibitors.
Chaudhary M; Singh V; Anvikar AR; Sahi S
Curr Comput Aided Drug Des; 2016; 12(4):282-293. PubMed ID: 27449897
[TBL] [Abstract][Full Text] [Related]
8. Plasmodium falciparum possesses a unique dual-specificity serine/threonine and tyrosine kinase, Pfnek3.
Low H; Chua CS; Sim TS
Cell Mol Life Sci; 2012 May; 69(9):1523-35. PubMed ID: 22116321
[TBL] [Abstract][Full Text] [Related]
9. Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1).
Chapman TM; Osborne SA; Bouloc N; Large JM; Wallace C; Birchall K; Ansell KH; Jones HM; Taylor D; Clough B; Green JL; Holder AA
Bioorg Med Chem Lett; 2013 May; 23(10):3064-9. PubMed ID: 23570789
[TBL] [Abstract][Full Text] [Related]
10. Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): Preparation and evaluation of pyrazole linked analogues.
Large JM; Osborne SA; Smiljanic-Hurley E; Ansell KH; Jones HM; Taylor DL; Clough B; Green JL; Holder AA
Bioorg Med Chem Lett; 2013 Nov; 23(21):6019-24. PubMed ID: 24035097
[TBL] [Abstract][Full Text] [Related]
11. Pfnek-1, a NIMA-related kinase from the human malaria parasite Plasmodium falciparum Biochemical properties and possible involvement in MAPK regulation.
Dorin D; Le Roch K; Sallicandro P; Alano P; Parzy D; Poullet P; Meijer L; Doerig C
Eur J Biochem; 2001 May; 268(9):2600-8. PubMed ID: 11322879
[TBL] [Abstract][Full Text] [Related]
12. Viability Screen of LOPAC
Tong JX; Ang SEL; Tan EHN; Tan KSW
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30718250
[TBL] [Abstract][Full Text] [Related]
13. Plasmodium kinases as targets for new-generation antimalarials.
Lucet IS; Tobin A; Drewry D; Wilks AF; Doerig C
Future Med Chem; 2012 Dec; 4(18):2295-310. PubMed ID: 23234552
[TBL] [Abstract][Full Text] [Related]
14. Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
Crowther GJ; Hillesland HK; Keyloun KR; Reid MC; Lafuente-Monasterio MJ; Ghidelli-Disse S; Leonard SE; He P; Jones JC; Krahn MM; Mo JS; Dasari KS; Fox AM; Boesche M; El Bakkouri M; Rivas KL; Leroy D; Hui R; Drewes G; Maly DJ; Van Voorhis WC; Ojo KK
PLoS One; 2016; 11(3):e0149996. PubMed ID: 26934697
[TBL] [Abstract][Full Text] [Related]
15. Nima- and Aurora-related kinases of malaria parasites.
Carvalho TG; Doerig C; Reininger L
Biochim Biophys Acta; 2013 Jul; 1834(7):1336-45. PubMed ID: 23462523
[TBL] [Abstract][Full Text] [Related]
16. Targeting the Plasmodium vivax equilibrative nucleoside transporter 1 (PvENT1) for antimalarial drug development.
Deniskin R; Frame IJ; Sosa Y; Akabas MH
Int J Parasitol Drugs Drug Resist; 2016 Apr; 6(1):1-11. PubMed ID: 26862473
[TBL] [Abstract][Full Text] [Related]
17. PfRIO-2 kinase is a potential therapeutic target of antimalarial protein kinase inhibitors.
Nag S; Prasad K; Bhowmick A; Deshmukh R; Trivedi V
Curr Drug Discov Technol; 2013 Mar; 10(1):85-91. PubMed ID: 23082912
[TBL] [Abstract][Full Text] [Related]
18. Cyclin-dependent protein kinases as therapeutic drug targets for antimalarial drug development.
Waters NC; Geyer JA
Expert Opin Ther Targets; 2003 Feb; 7(1):7-17. PubMed ID: 12556199
[TBL] [Abstract][Full Text] [Related]
19. Picomolar Inhibition of Plasmepsin V, an Essential Malaria Protease, Achieved Exploiting the Prime Region.
Gambini L; Rizzi L; Pedretti A; Taglialatela-Scafati O; Carucci M; Pancotti A; Galli C; Read M; Giurisato E; Romeo S; Russo I
PLoS One; 2015; 10(11):e0142509. PubMed ID: 26566224
[TBL] [Abstract][Full Text] [Related]
20. Trisubstituted thiazoles as potent and selective inhibitors of Plasmodium falciparum protein kinase G (PfPKG).
Tsagris DJ; Birchall K; Bouloc N; Large JM; Merritt A; Smiljanic-Hurley E; Wheldon M; Ansell KH; Kettleborough C; Whalley D; Stewart LB; Bowyer PW; Baker DA; Osborne SA
Bioorg Med Chem Lett; 2018 Oct; 28(19):3168-3173. PubMed ID: 30174152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
